Format

Send to

Choose Destination
See comment in PubMed Commons below
Cancer Discov. 2013 Feb;3(2):145-7. doi: 10.1158/2159-8290.CD-12-0585.

Activating mutations in HER2: neu opportunities and neu challenges.

Author information

1
Department of Pathology, Memorial Sloan-Kettering Cancer Center, New York, New York 10065, USA.

Abstract

Twenty-five years after the publication of seminal studies showing that HER2 gene amplification and protein overexpression are oncogenic in breast cancer, Bose and colleagues report on the identification of activating HER2 somatic mutations that, albeit rare, may determine the response of breast cancer cells to anti-HER2 agents. These results herald a new era for the potential use of existing HER2-targeted agents for the treatment of patients with HER2-mutant breast cancer.

PMID:
23400474
DOI:
10.1158/2159-8290.CD-12-0585
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center